1. Macrophage-derived interleukin-6 is necessary and sufficient for choroidal angiogenesis
- Author
-
Jeremy A. Lavine, Harris Perlman, Carla M. Cuda, and Steven Droho
- Subjects
musculoskeletal diseases ,genetic structures ,Angiogenesis ,Science ,medicine.medical_treatment ,Monocytes ,Article ,Mice ,medicine ,Animals ,Humans ,Macrophage ,STAT3 ,Interleukin 6 ,Monocytes and macrophages ,Sprouting angiogenesis ,Multidisciplinary ,biology ,Choroid ,Interleukin-6 ,business.industry ,Macrophages ,Macular degeneration ,Receptors, Interleukin-6 ,Choroidal Neovascularization ,eye diseases ,Disease Models, Animal ,Choroidal neovascularization ,Cytokine ,STAT protein ,biology.protein ,Cancer research ,Medicine ,Disease Susceptibility ,sense organs ,medicine.symptom ,business ,Biomarkers - Abstract
Neovascular age-related macular degeneration (nAMD) commonly causes vision loss from aberrant angiogenesis, termed choroidal neovascularization (CNV). Interleukin-6 (IL6) is a pro-inflammatory and pro-angiogenic cytokine that is correlated with AMD progression and nAMD activity. We hypothesize that anti-IL6 therapy is a potential nAMD therapeutic. We found that IL6 levels were increased after laser injury and expressed by macrophages. Il6-deficiency decreased laser-induced CNV area and exogenous IL6 addition increased choroidal sprouting angiogenesis. Il6-null mice demonstrated equally increased macrophage numbers as wildtype mice. At steady state, IL6R expression was detected on peripheral blood and ocular monocytes. After laser injury, the number of IL6R+Ly6C+ monocytes in blood and IL6R+ macrophages in the eye were increased. In human choroid, macrophages expressed IL6, IL6R, and IL6ST. Furthermore, IL6R+ macrophages displayed a transcriptional profile consistent with STAT3 (signal transducer and activator of transcription 3) activation and angiogenesis. Our data show that IL6 is both necessary and sufficient for choroidal angiogenesis. Macrophage-derived IL6 may stimulate choroidal angiogenesis via classical activation of IL6R+ macrophages, which then stimulate angiogenesis. Targeting IL6 or the IL6R could be an effective adjunctive therapy for treatment-resistant nAMD patients.
- Published
- 2021
- Full Text
- View/download PDF